Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
| Image |  |
|---|---|
| Description | scientific article published on 27 January 2020 |
| Author/s |
author: Athena Philis-Tsimikas Andrej Janež |
| Publication date | January 27, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |